Global Biosimilar Market Insights, Forecast to 2025

2 Global Biosimilar Quarterly Market Size Analysis

• 2.1 Biosimilar Business Impact Assessment - COVID-19
  • 2.1.1 Global Biosimilar Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Biosimilar Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Biosimilar Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Biosimilar Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Biosimilar Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Biosimilar Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Biosimilar Market
• 3.5 Key Manufacturers Biosimilar Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Biosimilar Segments, By Type

• 4.1 Introduction
  • 1.4.1 Human Growth Hormones
  • 1.4.2 Monoclonal Antibodies
  • 1.4.3 Insulin
  • 1.4.4 Peptides
  • 1.4.5 Erythropoietin
  • 1.4.6 Others
• 4.2 By Type, Global Biosimilar Market Size, 2019-2021
  • 4.2.1 By Type, Global Biosimilar Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Biosimilar Price, 2020-2021

5 Impact of Covid-19 on Biosimilar Segments, By Application

• 5.1 Overview
  • 5.5.1 Oncology
  • 5.5.2 Chronic and Autoimmune Diseases
  • 5.5.3 Growth Hormone Deficiency
  • 5.5.4 Infectious Diseases
  • 5.5.5 Others
• 5.2 By Application, Global Biosimilar Market Size, 2019-2021
  • 5.2.1 By Application, Global Biosimilar Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Biosimilar Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Allergan plc
  • 7.1.1 Allergan plc Business Overview
  • 7.1.2 Allergan plc Biosimilar Quarterly Production and Revenue, 2020
  • 7.1.3 Allergan plc Biosimilar Product Introduction
  • 7.1.4 Allergan plc Response to COVID-19 and Related Developments
• 7.2 BIOCAD
  • 7.2.1 BIOCAD Business Overview
  • 7.2.2 BIOCAD Biosimilar Quarterly Production and Revenue, 2020
  • 7.2.3 BIOCAD Biosimilar Product Introduction
  • 7.2.4 BIOCAD Response to COVID-19 and Related Developments
• 7.3 Biocon
  • 7.3.1 Biocon Business Overview
  • 7.3.2 Biocon Biosimilar Quarterly Production and Revenue, 2020
  • 7.3.3 Biocon Biosimilar Product Introduction
  • 7.3.4 Biocon Response to COVID-19 and Related Developments
• 7.4 BioXpress Therapeutics
  • 7.4.1 BioXpress Therapeutics Business Overview
  • 7.4.2 BioXpress Therapeutics Biosimilar Quarterly Production and Revenue, 2020
  • 7.4.3 BioXpress Therapeutics Biosimilar Product Introduction
  • 7.4.4 BioXpress Therapeutics Response to COVID-19 and Related Developments
• 7.5 Boehringer Ingelheim
  • 7.5.1 Boehringer Ingelheim Business Overview
  • 7.5.2 Boehringer Ingelheim Biosimilar Quarterly Production and Revenue, 2020
  • 7.5.3 Boehringer Ingelheim Biosimilar Product Introduction
  • 7.5.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
• 7.6 Celltrion
  • 7.6.1 Celltrion Business Overview
  • 7.6.2 Celltrion Biosimilar Quarterly Production and Revenue, 2020
  • 7.6.3 Celltrion Biosimilar Product Introduction
  • 7.6.4 Celltrion Response to COVID-19 and Related Developments
• 7.7 Coherus BioSciences
  • 7.7.1 Coherus BioSciences Business Overview
  • 7.7.2 Coherus BioSciences Biosimilar Quarterly Production and Revenue, 2020
  • 7.7.3 Coherus BioSciences Biosimilar Product Introduction
  • 7.7.4 Coherus BioSciences Response to COVID-19 and Related Developments
• 7.8 Dr. Reddy’s Laboratories
  • 7.8.1 Dr. Reddy’s Laboratories Business Overview
  • 7.8.2 Dr. Reddy’s Laboratories Biosimilar Quarterly Production and Revenue, 2020
  • 7.8.3 Dr. Reddy’s Laboratories Biosimilar Product Introduction
  • 7.8.4 Dr. Reddy’s Laboratories Response to COVID-19 and Related Developments
• 7.9 Genor BioPharma
  • 7.9.1 Genor BioPharma Business Overview
  • 7.9.2 Genor BioPharma Biosimilar Quarterly Production and Revenue, 2020
  • 7.9.3 Genor BioPharma Biosimilar Product Introduction
  • 7.9.4 Genor BioPharma Response to COVID-19 and Related Developments
• 7.10 Intas Pharmaceuticals Limited
  • 7.10.1 Intas Pharmaceuticals Limited Business Overview
  • 7.10.2 Intas Pharmaceuticals Limited Biosimilar Quarterly Production and Revenue, 2020
  • 7.10.3 Intas Pharmaceuticals Limited Biosimilar Product Introduction
  • 7.10.4 Intas Pharmaceuticals Limited Response to COVID-19 and Related Developments
• 7.11 Novartis
  • 7.11.1 Novartis Business Overview
  • 7.11.2 Novartis Biosimilar Quarterly Production and Revenue, 2020
  • 7.11.3 Novartis Biosimilar Product Introduction
  • 7.11.4 Novartis Response to COVID-19 and Related Developments
• 7.12 Pfizer
  • 7.12.1 Pfizer Business Overview
  • 7.12.2 Pfizer Biosimilar Quarterly Production and Revenue, 2020
  • 7.12.3 Pfizer Biosimilar Product Introduction
  • 7.12.4 Pfizer Response to COVID-19 and Related Developments
• 7.13 Reliance Life Sciences
  • 7.13.1 Reliance Life Sciences Business Overview
  • 7.13.2 Reliance Life Sciences Biosimilar Quarterly Production and Revenue, 2020
  • 7.13.3 Reliance Life Sciences Biosimilar Product Introduction
  • 7.13.4 Reliance Life Sciences Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Biosimilar Supply Chain Analysis
  • 8.1.1 Biosimilar Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Biosimilar Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Biosimilar Distribution Channels
  • 8.2.2 Covid-19 Impact on Biosimilar Distribution Channels
  • 8.2.3 Biosimilar Distributors
• 8.3 Biosimilar Customers

9 Key Findings

10 Appendix

• 10.1 About Us